FDA offers opportunities to firms marketing prescription laxatives containing polyethylene glycol 3350, which Schering-Plough has marketed OTC with MiraLax since late 2007, to contest the agency's proposal to withdraw approval for the Rx products. In an Oct. 24 Federal Register notice, FDA says in April 2007 it proposed withdrawing the abbreviated new drug applications for PEG 3350 held by Schwarz Pharma, Kali Laboratories, Nexgen Pharma, Coastal Pharmaceuticals and Teva Pharmaceutical Industries. After approving the MiraLax switch application in December 2006, FDA was required to remove prescription PEG 3350 drugs from the market because the Food, Drug and Cosmetic Act does not permit both Rx and OTC versions of the same product to be marketed at the same time, the agency says. None of the five manufacturers with an ANDA for prescription PEG 3350 have asked about changing their product labels to the approved OTC labeling or about voluntarily withdrawing the ANDAs. Each of the five firms has until Nov. 24 to ask FDA to schedule a hearing to contest the proposal. According to the notice, S-P's exclusivity for OTC MiraLax sales expired this month
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
Sponsors can expect faster evaluation processes for key medicines and greater support in mitigating medicines supply shortages this year as part of the European Medicines Agency’s digital transformation overhaul.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.
By stepping into the role of the Centers for Disease Control and Advisory Committee on Immunization Practices, HHS Secretary Robert F. Kennedy Jr. is causing further confusion and uncertainty about vaccine policy, experts say.